Expanding into international markets isn’t optional for pharmaceutical companies but a necessary step towards growth. However, major regions like the US, EU, and Japan each have their regulators, which adds complexity to regulatory translation processes. For companies looking to penetrate these markets, it’s important to understand the rules set down by each supervisory agency.
For example, the Food and Drug Administration (FDA) handles approvals for the US region. Similarly, the European Medicines Agency (EMA) is responsible for EU member states, but submission formats and document structures are different. There are also differences in formatting and language in non-English markets like China, with the National Medical Products Administration (NMPA).
In essence, preparing documents for drug regulatory submission requires more than basic translations. You need effective localization to ensure accuracy, consistency, and compliance across all markets. It’s also important that your content meets the local regulatory requirements for each region to guarantee successful global submissions.
Key Regulatory Documents Required for Global Submissions
International drug submissions require a standardized set of documents. Most regulatory bodies, including the FDA and EMA, use the electronic Common Technical Document (eCTD) structure. This framework consists of five modules, an XML backbone, and a defined folder hierarchy. Module 1 varies by market (FDA, EMA, Health Canada, and over 60 other agencies), while modules 2-5 are harmonized globally.
Understanding the eCTD structure is fundamental to successful drug submissions. Here’s a breakdown of each module alongside its specific purposes:
- Module 1 (administrative information) – This includes cover letters, application forms, and product labeling for specific regions. It’s composed of 50-200 documents.
- Module 2 (summaries) – This consists of high-level overviews of quality, clinical, and nonclinical data. There are around 30-50 documents in this module.
- Module 3 (quality / CMC) – This covers manufacturing, including drug substance, composition, and stability. The document size needed for this is 200-1,000.
- Module 4 (nonclinical study reports) – This comprises pharmacology, PK, and toxicology studies. It requires around 50-300 docs.
- Module 5 (clinical study reports) – This module features all data from human trials and reports from clinical studies. For this, approximately 500-1,000 documents are required.
Because module 1 varies by market, it must be adapted to each. This is a key area where pharmaceutical translation services become very important for success. In addition to eCTD, various supporting documents should be prepared by your company. They include:
- Investigational New Drug (IND) applications for clinical trials
- New Drug Applications (NDA) or Marketing Authorization Applications (MAA)
- Labeling materials, such as Instructions for Use (IFUs) and patient leaflets
Depending on the region you’re targeting, these documents will need regulatory translation and formatting changes to meet standards. Apart from language, regional differences extend to more complex elements. For instance, the FDA requires specific forms, while the EMA uses standardized templates like the Summary of Product Characteristics (SmPC). Other agencies like Japan’s PMDA have their own unique structures and submission portals. In summary, what’s important during submissions is that your format, terminology, and document structure must match local requirements.
Key Challenges in Preparing Multilingual Submission Documents
Putting together your multilingual documents for global submissions is a complex process. Each file must be linguistically consistent, scientifically accurate, and completely aligned with each region’s regulatory landscape. Some of the most common challenges often encountered are presented below.
Inconsistent terminology across dossiers
Whenever different terms are used to describe the same concepts across languages, it may lead to reliability concerns from regulators. What happens is that this slows down approval timelines due to clarification requests and resubmissions. Terminology consistency is especially critical in sections that have to do with safety, labeling, and clinical outcomes.
Poor translation quality
Since regulatory documents are highly technical, minor errors in translation can alter meanings. This can bring about risks of submission delays, total rejections, or even misinterpretation of the clinical or safety data. Authorities like the FDA and NMPA require precise and validated language translations in every submission.
Last-minute updates
During the final review stages, changes may often be made to regulatory documents, which then creates new risks. Usually, this happens when updates aren’t synchronized properly across all languages, leading to mismatches between modules. This will then result in submission inconsistencies and even trigger validation failures in electronic systems such as eCTD.
Managing parallel submissions across regions
Because you’re submitting to multiple regulatory authorities at the same time, your submissions need to be coordinated. Also, any updates made to the documents must reflect in parallel across languages and regional formats. Managing each submitted version efficiently reduces the risk of errors, delays, or outright rejections.
Varying local regulatory requirements
Another complexity that adds a layer of challenge in submissions has to do with the different regulatory rules. Each region may require different labeling structures, terminologies, and formatting rules, which could be complicated sometimes. For example, what is accepted in an EMA submission may not align with FDA expectations. This will require you to create country-specific adaptations on the same core document.
Best Practices for Submission-Ready Multilingual Documentation
To manage the complexities in regulatory translation, you need to incorporate a structured approach to documentation. These are the best practices that can help guarantee that your submissions are accurate, consistent, and ready for review.
- Align translation workflows with submission timelines – Translations for your drug regulatory submission should not begin at the final stage. It’s important to plan your workflow in alignment with the regulator’s timelines to avoid rushed work and minimize errors.
- Centralize terminology for cross-Market consistency – Using a single terminology database is critical because it features standard medical phrases and product names. A centralized glossary ensures that similar terms are used across all modules and languages to limit regulatory queries.
- Prepare for rolling submissions and ongoing updates – Because regulatory submissions can evolve, new updates or corrections may be added late in the process. Your team should set up a system that accepts updates across all markets without altering consistency in the documents.
- Work with qualified life sciences linguists – Global drug submissions require subject-matter expertise, so it’s essential to work with linguists who are qualified in life sciences. These professionals understand medical terminology, clinical data, and regulatory expectations, which improves the overall quality of your documents.
- Implement validated linguistic and quality assurance processes – Incorporating a strong quality framework is essential if you want your submissions to be accurate and fully compliant. You can implement multi-step reviews to check translations or the use of memory tools for consistency.
- Ensure traceability, version control, and audit readiness – Clear version control ensures that your teams work on the latest documents concurrently. It’s also important to keep detailed records so changes are traceable and audits can be done at any time.
Conclusion
Carrying out accurate and consistent multilingual documentation is crucial for success in global drug submissions. Each regulatory authority in various regions expects documents to meet strict language, format, and technical standards. Failing to prepare properly will not only affect your documentation quality; it also impacts submission timelines and overall success. Companies that make the effort to invest in regulatory translation services are better positioned to avoid costly setbacks and meet regulatory expectations.
At EC Innovations, we provide specialized translation and localization services for pharmaceutical and regulatory documents. Our team comprises experts who manage complex multilingual regulatory projects with efficiency to ensure accuracy and compliance. If you’re looking to prepare regulatory documents for global drug submissions, contact us today for consultations on our services.
